Kamada (NASDAQ:KMDA) Shares Break Above Two Hundred Day Moving Average – Here’s Why

Kamada Ltd. (NASDAQ:KMDA – Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.00 and traded as high as $8.14. Kamada shares last traded at $8.10, with a volume of 206,789 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Stifel Nicolaus set a $12.00 price objective on Kamada in a report on Monday. Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Finally, UBS Group reiterated a “buy” rating and set a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Kamada has a consensus rating of “Buy” and an average price target of $13.75.

Check Out Our Latest Research Report on Kamada

Kamada Stock Performance

The company has a market cap of $467.52 million, a PE ratio of 18.91, a PEG ratio of 0.68 and a beta of 0.90. The company’s 50-day simple moving average is $8.06 and its 200 day simple moving average is $8.00.

Kamada (NASDAQ:KMDA – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. The business had revenue of $52.03 million for the quarter, compared to analyst estimates of $52.51 million. Kamada had a return on equity of 9.36% and a net margin of 12.67%. Analysts forecast that Kamada Ltd. will post 0.48 EPS for the current year.

Kamada Announces Dividend

The business also recently disclosed a special dividend, which will be paid on Wednesday, December 9th. Stockholders of record on Thursday, November 19th will be paid a $0.14 dividend. The ex-dividend date is Thursday, November 19th. Kamada’s dividend payout ratio (DPR) is presently 97.67%.

Institutional Trading of Kamada

A number of large investors have recently made changes to their positions in KMDA. Aristides Capital LLC raised its holdings in Kamada by 4.5% in the first quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 1,476 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Kamada by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 1,346 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Kamada during the 3rd quarter worth approximately $25,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

See Also

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.